Filing Flows › Roivant Sciences (ROIV) › Q2 FY26
Roivant Sciences (ROIV) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Nov 10, 2025
Roivant Sciences (ROIV) reported revenue of $1.6M for the second quarter fiscal 2026 (Q2 FY26), -65% from a year earlier and -28% from the quarter before.
Roivant Sciences, Q2 FY26: revenue $1.6M (-65% year over year), net loss $166M, operating cash flow −$186M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -28% | -65% |
| Operating profit | −$306M | — | — |
| Net earnings | −$166M | — | — |
| Operating cash flow | −$186M | — | — |
What changed
Revenue was $1.6M in Q2 FY26, down 65% year over year and down 28% from the previous quarter.
Operating costs exceeded revenue by $306.2M, an operating margin of -19492.9%. Total costs fell 11% while revenue fell 65%. The fastest-growing cost line was Research & development (+15%). The quarter ended with a net loss of $166.0M, narrower than the previous quarter's $273.9M loss. Minority interests bore $52.5M of it: to shareholders the quarter was a loss of $113.5M. Non-operating items added $147.2M, -93% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$185.7M. Non-cash charges added back $921K of depreciation and amortization and $81.8M of share-based compensation. Working capital and other items used $102.4M. Capital expenditures of $7.8M exceeded it, leaving free cash flow of −$193.5M.
Questions
What was Roivant Sciences' revenue in the second quarter fiscal 2026?
Roivant Sciences (ROIV) reported revenue of $1.6M for the second quarter fiscal 2026 (Q2 FY26), -65% from a year earlier and -28% from the quarter before.
Source: Roivant Sciences 10-Q on SEC EDGAR.